A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm

Ann Allergy. 1987 Aug;59(2):107-9.


Inhaled albuterol and cromolyn by spinhaler have both been shown to be effective in the treatment of exercise-induced bronchospasm. Eighty subjects with exercise-induced bronchospasm participated in a randomized parallel group study comparing albuterol (180 microgram) and cromolyn (20 mg) administered 15 minutes prior to a standardized treadmill challenge. The cromolyn group was restudied after 2 and 4 weeks of 4 times/day cromolyn therapy. The albuterol group was also studied at 2 and 4 weeks, but they only used their inhaler as needed between study visits. The mean maximum FEV1 drop post-exercise in the albuterol group improved from 33% (screening visit) to 6% (treatment day 1). The cromolyn group showed significantly less (P less than .01) improvement than the albuterol group (31% drop at the screening visit to 14% drop at treatment day 1). When 2 or 4 weeks of continuous cromolyn therapy was given in addition to a dosage 15 minutes prior to exercise, there was no significant difference compared with acute cromolyn administration alone. In summary, acute administration of albuterol was better prophylaxis for exercise-induced bronchospasm than acute or chronic cromolyn treatment.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Adult
  • Albuterol / administration & dosage
  • Albuterol / therapeutic use*
  • Asthma / drug therapy*
  • Asthma, Exercise-Induced / drug therapy*
  • Child
  • Clinical Trials as Topic
  • Cromolyn Sodium / administration & dosage
  • Cromolyn Sodium / therapeutic use*
  • Humans
  • Lung Volume Measurements
  • Middle Aged
  • Random Allocation
  • Self Administration


  • Cromolyn Sodium
  • Albuterol